References
- Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366:158–164.
- Danby FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin. 2010;28(4):779–793. doi:https://doi.org/10.1016/j.det.2010.07.003.
- Garg A, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77(1):118–122. doi:https://doi.org/10.1016/j.jaad.2017.02.005.
- Canoui-Poitrine F, Le Thuaut A, Revuz JE, et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol. 2013;133(6):1506–1511. doi:https://doi.org/10.1038/jid.2012.472.
- Matusiak L, Bieniek A, Szepietowski JC. Hidradenitis suppurativa and associated factors: still unsolved problems. J Am Acad Dermatol. 2009;61(2):362–365. doi:https://doi.org/10.1016/j.jaad.2009.03.043.
- Garg A, Wertenteil S, Baltz R, et al. Prevalence estimates for hidradenitis suppurativa among children and adolescents in the United States: a gender- and age-adjusted population analysis. J Invest Dermatol. 2018;138(10):2152–2156. doi:https://doi.org/10.1016/j.jid.2018.04.001.
- Andersen RK, Jemec GB. Treatments for hidradenitis suppurativa. Clin Dermatol. 2017;35(2):218–224. doi:https://doi.org/10.1016/j.clindermatol.2016.10.018.
- Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422–434. doi:https://doi.org/10.1056/NEJMoa1504370.
- Fotiadou C, Vakirlis E, Ioannides D. Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa. Clin Cosmet Investig Dermatol. 2016;9:367–372. doi:https://doi.org/10.2147/CCID.S93619.
- Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105–115. doi:https://doi.org/10.2147/CCID.S111019.
- Vekic DA, Frew J, Cains GD. Hidradenitis suppurativa, a review of pathogenesis, associations and management. Part 1. Australas J Dermatol. 2018;59(4):267–277. doi:https://doi.org/10.1111/ajd.2018.59.issue-4.
- Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol. 2010;2(1):9–16. doi:https://doi.org/10.4161/derm.2.1.12490.
- Yadav S, Singh S, Edakkanambeth Varayil J, et al. Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(1):65–70. doi:https://doi.org/10.1016/j.cgh.2015.04.173.
- Sahin MT, Oztürkcan S, Türel-Ermertcan A, et al. Behçet’s disease associated with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2007;21(3):428–429. doi:https://doi.org/10.1111/j.1468-3083.2006.01922.x.
- Alzaga Fernandez AG, Demirci H, Darnley-Fisch DA, Steen DW. Interstitial keratitis secondary to severe hidradenitis suppurativa: a case report and literature review. Cornea. 2010;29(10):1189–1191. doi:https://doi.org/10.1097/ICO.0b013e3181d4fd5c.
- Mahmood MA, Pillai S, Limaye SR. Peripheral ulcerative keratitis associated with hideradenitis suppurativa. Cornea. 1991;10(1):75–78. doi:https://doi.org/10.1097/00003226-199101000-00016.
- Meskin SW, Carlson EM. Mooren’s-type ulceration associated with severe hidradenitis suppurativa: a case report and literature review. Ocul Immunol Inflamm. 2011;19(5):340–342. doi:https://doi.org/10.3109/09273948.2011.584653.
- Saygın D, Syed AU, Lowder CY, et al. Characteristics of inflammatory eye disease associated with hidradenitis suppurativa. Eur J Rheumatol. 2018;5(3):165–168. doi:https://doi.org/10.5152/eurjrheumatol.
- Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California epidemiology of Uveitis Study. Ophthalmology. 2004;111:(3):491–500. doi:https://doi.org/10.1016/j.ophtha.2003.06.014. discussion.
- Sen HN, Davis J, Ucar D, et al. Gender disparities in ocular inflammatory disorders. Curr Eye Res. 2015;40(2):146–161. doi:https://doi.org/10.3109/02713683.2014.932388.
- Suhler EB, Lloyd MJ, Choi D, et al. Incidence and prevalence of uveitis in veterans affairs medical centers of the Pacific Northwest. Am J Ophthalmol. 2008;146(6):890–6.e8. doi:https://doi.org/10.1016/j.ajo.2008.09.014.
- Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation study. JAMA Ophthalmol. 2013;131(11):1405–1412. doi:https://doi.org/10.1001/jamaophthalmol.2013.4237.
- Angeles-Han ST, McCracken C, Yeh S, et al. The association of race with childhood uveitis. Am J Ophthalmol. 2015;160(5):919–28.e1. doi:https://doi.org/10.1016/j.ajo.2015.08.002.
- Balevic SJ, Rabinovich CE. Profile of adalimumab and its potential in the treatment of uveitis. Drug Des Devel Ther. 2016;10:2997–3003. doi:https://doi.org/10.2147/DDDT.S94188.
- Durrani K, Kempen JH, Ying GS, et al. Adalimumab for ocular inflammation. Ocul Immunol Inflamm. 2017;25(3):405–412. doi:https://doi.org/10.3109/09273948.2015.1134581.
- Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008;358(24):2594–2605. doi:https://doi.org/10.1056/NEJMcp0801880.
- De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906–918. doi:https://doi.org/10.1016/S0140-6736(16)00278-6.
- Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves’ disease-real life data. Endocrine. 2017;56(3):568–578. doi:https://doi.org/10.1007/s12020-017-1306-5.